ATRICURE, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.92 USD | -2.26% |
|
-8.57% | -35.16% |
Financials (USD)
| Sales 2024 * | 461M | Sales 2025 * | 526M | Capitalization | 1.13B |
|---|---|---|---|---|---|
| Net income 2024 * | -34M | Net income 2025 * | -27M | EV / Sales 2024 * | 2.33 x |
| Net cash position 2024 * | 61.14M | Net cash position 2025 * | 78.13M | EV / Sales 2025 * | 2.01 x |
| P/E ratio 2024 * |
-31.9
x | P/E ratio 2025 * |
-40.9
x | Employees | 1,200 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.92% |
More Fundamentals
* Assessed data
More news
Latest transcript on AtriCure, Inc.
More recommendations
More press releases
More news
| 1 day | +1.52% | ||
| 1 week | -9.46% | ||
| Current month | -22.91% | ||
| 1 month | -27.04% | ||
| 3 months | -29.81% | ||
| 6 months | -34.06% | ||
| Current year | -34.30% |
1 week
22.42
24.97
1 month
22.4232.08
Current year
22.4239.05
1 year
22.4259.61
3 years
22.4289.18
5 years
22.4289.18
10 years
13.1989.18
| Managers | Title | Age | Since |
|---|---|---|---|
Michael Carrel
CEO | Chief Executive Officer | 53 | 12-11-01 |
Angela Wirick
DFI | Director of Finance/CFO | 46 | 14-06-30 |
| Chief Tech/Sci/R&D Officer | 52 | 17-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Karen Prange
BRD | Director/Board Member | 60 | 19-12-03 |
Michael Carrel
CEO | Chief Executive Officer | 53 | 12-11-01 |
Sven Wehrwein
BRD | Director/Board Member | 73 | 16-11-09 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.12% | 509 M€ | -.--% | ||
| 0.03% | 773 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 23.08 | -1.60% | 26 851 |
| 24-04-17 | 23.45 | +1.52% | 1,057,560 |
| 24-04-16 | 23.1 | +0.87% | 1,111,445 |
| 24-04-15 | 22.9 | -4.94% | 1,315,355 |
| 24-04-12 | 24.09 | -4.82% | 561,606 |
Delayed Quote Nasdaq, April 17, 2024 at 04:00 pm EDT
More quotes
AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.
Calendar
2024-05-01
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
23.45
USD
Average target price
54.38
USD
Spread / Average Target
+131.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -34.30% | 1.13B | |
| -4.01% | 105B | |
| -4.77% | 67.09B | |
| +7.87% | 51.61B | |
| +16.18% | 47.55B | |
| +0.60% | 39.95B | |
| +7.17% | 27.62B | |
| -1.23% | 25.62B | |
| -12.86% | 25.74B | |
| +11.40% | 24.93B |
- Stock Market
- Equities
- ATRC Stock
